bevacizumab,cetuzumab 
roche,Merck 
[]
we spoke with yu sunakawa who discussed results of a survival analysis of the phase ii deeper trial of m-folfoxiri + cetuzumab vs m-folfoxiri + bevacizumab in unresectable ras + braf wt mcrc more on #gi23 #gism #colorectalcancer #crcsm 
The Video Journal of Oncology is dedicated to providing up-to-date information & international expertise on #Oncology #BCsm #LCsm #GUsm #GIsm #PCsm #CRCsm